Personalized Ocular Therapy Systems

A novel lacrimal system integrating AI, IoT, blockchain, and nanomaterials to provide targeted, data-driven, and secure drug delivery to the eye, addressing unmet needs in ocular disease management.

The original lacrimal system patent addressed challenges in drug delivery to the eye, but limitations in personalized treatment, data security, and real-time monitoring hindered its effectiveness. The new inventive concept combines the lacrimal system with cutting-edge technologies to overcome these limitations, providing a more comprehensive and efficient solution for ocular disease management.

The inventive concept integrates the lacrimal system device with an AI-powered diagnostic module for identifying ocular diseases, a blockchain-based secure data storage for storing patient medical records, and an IoT-enabled sensor for monitoring eye health. The system utilizes a nanomaterial-enhanced coating for controlled release of active agents and a micro-needle array for minimally invasive insertion into the eye. The wearable device with an integrated AI-powered assistant reminds patients to administer medication, and the cloud-based platform enables remote monitoring and analytics.

The new claims introduce the synergistic combination of AI, IoT, blockchain, and nanomaterials with the lacrimal system, providing a novel and non-obvious solution for personalized ocular therapy. The integration of these technologies enables real-time monitoring, data-driven treatment, and secure data storage, which are not present in the original patent.

Alternative embodiments may include the use of different AI algorithms, varying IoT sensor configurations, or alternative blockchain platforms. The inventive concept could also be adapted for use in other areas of medicine, such as respiratory or dermatological disease management.

The personalized ocular therapy system has significant commercial potential in the ocular disease management market, with potential applications in pharmaceutical companies, medical device manufacturers, and healthcare providers. The system's ability to provide targeted, data-driven, and secure treatment could lead to improved patient outcomes, reduced healthcare costs, and increased market share.